ANAL

ECOG/ACRIN-EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO®), after standard chemotherapy {(mitomycin-C and 5-fluorouracil (5-FU) or capecitabine) or 5-FU and cisplatin} and radiation will prevent anal cancer from returning.

Learn more about the ECOG/ACRIN-EA2165 trial or call the Protocol Office at 484-628-8193.

ECOG/ACRIN-EA2182: A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)

The purpose of this study is to compare lower-dose chemoradiation therapy to standard-dose chemoradiation therapy.

Learn more about the ECOG/ACRIN-EA2182 trial or call the Protocol Office at 484-628-8193.

COLON/RECTAL

Alliance-A021502: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone.

Learn more about the Alliance-A021502 trial or call the Protocol Office at 484-628-8193.

SWOG-S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

The purpose of this screening step is to perform a genetic test on a colorectal cancer tumor sample to see if it has a HER-2 gene amplification. HER-2 is a human gene that makes a protein also called HER-2.

Learn more about the SWOG-S1613 trial or call the Protocol Office at 484-628-8193.

NRG-GI004: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

The purpose of this screening step is to perform a genetic test on the colorectal cancer tumor sample to see if it has a HER-2 gene amplification.

Learn more about the NRG-GI004 trial or call the Protocol Office at 484-628-8193.

NRG-GI005: Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA).

A purpose of this study is for the study doctors to learn if a ctDNA test done after your surgery for colon cancer is helpful to decide if you should receive chemotherapy.

Learn more about the NRG-GI005 trial or call the Protocol Office at 484-628-8193.

ESOPHAGEAL AND GASTRIC

ECOG/ACRIN-EA2183: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma

The purpose of this study is to compare the usual treatment, which consists of chemotherapy alone, to chemotherapy plus the addition of radiation.

Learn more about the ECOG/ACRIN-EA2183 trial or call the Protocol Office at 484-628-8193.

GASTROESOPHAGEAL JUNCTION

Pharmaceutical- BGB-A317-305: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

The purpose of this study is to compare the effects and safety of tislelizumab plus chemotherapy, to placebo (an inactive substance) plus chemotherapy, on the patient’s Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJ).

Learn more about the Pharmaceutical- BGB- A317-305 trial or call the Protocol Office at 484-628-8193.

PANCREATIC

FibroGen/FGCL-3019-087: A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer.

The purpose of this study is to evaluate whether pamrevlumab, given in combination with the currently approved chemotherapy treatment (gemcitabine and nab-paclitaxel), when compared to placebo, is effective and safe in the treatment of patients with locally advanced unresectable (cannot be completely removed by surgery) pancreatic cancer.

Learn more about the FibroGen/FGCL-3019-087 trial or call the Protocol Office at 484-628-8193.

M16-142/AbbVie: Creon® (Pancrelipase) Therapy for Subjects with Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-Blind, Randomized, Parallel Design with 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-Label Single Dose Cohort in Non-Resected Pancreatic Cancer Subjects.

The purpose of this study is to evaluate the effects of 2 different dose levels of pancrelipase on dietary fat absorption and Exocrine Pancreatic Insufficiency (EPI) symptoms in patients with pancreatic cancer and EPI.

Learn more about the M16-142/AbbVie trial or call the Protocol Office at 484-628-8193.